Nanoparticle albumin-bound (nab)-paclitaxel, an albumin-stabilized paclitaxel formulation, demonstrates clinical activity when administered in combination with gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (PDA). The limited availability of patient tissue and exquisite sensitivity of xenografts to chemotherapeutics have limited our ability to address the mechanistic basis of this treatment regimen. Here, we used a mouse model of PDA to show that the coadministration of nab-paclitaxel and gemcitabine uniquely demonstrates evidence of tumor regression. Combination treatment increases intratumoral gemcitabine levels attributable to a marked decrease in the primary gemcitabine metabolizing enzyme, cytidine deaminase. Correspondingly, paclitaxel reduced the levels of cytidine deaminase protein in cultured cells through reactive oxygen species–mediated degradation, resulting in the increased stabilization of gemcitabine. Our findings support the concept that suboptimal intratumoral concentrations of gemcitabine represent a crucial mechanism of therapeutic resistance in PDA and highlight the advantages of genetically engineered mouse models in preclinical therapeutic trials.
Significance: This study provides mechanistic insight into the clinical cooperation observed between gemcitabine and nab-paclitaxel in the treatment of pancreatic cancer. Cancer Discovery; 2(3); 260–9. ©2012 AACR.
Read the Commentary on this article by Clark, p. 208
This article is highlighted in the In This Issue feature, p. 193
Pancreatic ductal adenocarcinoma (PDA) remains one of the most aggressive tumors in humans. A striking clinical feature of PDA is its innate resistance to available chemotherapies, resulting in a 5-year survival rate of less than 5%. The standard systemic chemotherapy for PDA is gemcitabine, but treatment with gemcitabine only marginally extends a patient's survival, and combinations with a second cytotoxic agent have so far proved largely ineffective (1, 2). Recent data in mice and humans suggest that poor drug delivery attributable to highly desmoplastic and hypovascular tumors and rapid metabolic inactivation of therapeutic agents may be at least partly responsible for this unusually poor response to treatment (3, 4).
Therefore, methods that can increase intratumoral gemcitabine levels in PDA are under active investigation. Recently, it was proposed that nanoparticle albumin-bound (nab)-paclitaxel, a water-soluble albumin-bound formulation of paclitaxel, could disrupt the PDA stromal architecture in tumor xenografts and induce reactive angiogenesis, resulting in increased perfusion and delivery of gemcitabine (5). nab-Paclitaxel initially was developed to avoid toxicities associated with oil-based solvents required to solubilize paclitaxel, such as Cremophor EL (BASF Corp; ref. 6). Preclinical and clinical data have demonstrated superior efficacy and safety of nab-paclitaxel over solvent-based paclitaxel (7, 8), thus leading to approval by the U.S. Food and Drug Administration in 2005 as a second-line therapy for the treatment of patients with metastatic breast cancer.
The mechanism of delivery of nab-paclitaxel has been proposed to be mediated by active transport of albumin into the interstitial space via gp60-mediated transcytosis (9). In addition, secreted protein, acidic and rich in cysteine (SPARC), also known as osteonectin, is highly expressed and secreted by PDA peritumoral fibroblasts (10) and may serve as an albumin-binding protein that sequesters nab-paclitaxel to concentrate the drug intratumorally. Elevated expression of SPARC has been correlated with improved response to nab-paclitaxel; however, this effect may be tumor-type specific (5, 11, 12). Given that PDA is a stromal-rich tumor with abundant SPARC expression, in a series of clinical trials investigators are evaluating the combination of nab-paclitaxel and gemcitabine in patients with metastatic PDA. Initial results from a phase I/II trial in stage IV pancreatic cancer patients recently were reported; they demonstrated promising clinical activity in patients with PDA (5). More recently, an international phase III trial was initiated for patients with metastatic pancreatic cancer who were randomized to gemcitabine or gemcitabine plus nab-paclitaxel (13).
In clinical trials, the investigation of mechanisms of actions of novel drug combinations is often hampered by the paucity of available tumor tissue for detailed pharmacologic, biochemical, and histologic analysis. Genetically engineered mouse models (GEMM) constitute a promising platform for preclinical testing of novel drugs because many GEMMs recapitulate the molecular and clinical features of the cognate human malignancy (14, 15). Because tumor tissue can be readily obtained at predefined time points, GEMMs enable the direct correlation between drug levels, response to treatment, and alterations at the cellular and molecular level. Thus, the potential efficacy of drug combinations and also mechanisms of resistance can be identified, guiding the selection and rapid translation of more effective therapies for human cancers.
We have previously described a GEMM of PDA that is based upon the pancreatic specific expression of endogenous mutant Kras and Trp53 alleles (16). Such mutant mice, termed KPC mice (LSL-KrasG12D; LSL-Trp53R172H; Pdx-1-Cre), develop primary pancreatic tumors that faithfully recapitulate the clinical, histopathologic, pharmacokinetic, and molecular features of the human disease (17). Furthermore, unlike many transplantation models of PDA, KPC mice demonstrate innate resistance to gemcitabine (3). Here, we investigated the antitumor efficacy and the molecular mechanism of action of nab-paclitaxel and gemcitabine in KPC mice.
Combination of nab-Paclitaxel and Gemcitabine Causes Tumor Regression and Reduces Metastasis
To test the efficacy of nab-paclitaxel in the KPC model, we treated mice with established tumors of comparable size for 8 days with vehicle, gemcitabine, nab-paclitaxel, or nab-paclitaxel/gemcitabine (Supplementary Fig. S1A and B). Consistent with clinical reports (18, 19), both nab-paclitaxel monotherapy and nab-paclitaxel/gemcitabine treatments were well tolerated, with blood counts found to be in acceptable ranges (Fig. 1A and Supplementary Fig. S1C). Mice treated with combination therapy were more likely to survive the entire treatment regimen (Fig. 1A). Furthermore, combination treatment modestly reduced metastasis incidence, and quantification of liver metastases revealed a significant decrease in metastatic burden in both the nab-paclitaxel cohort and the nab-paclitaxel/gemcitabine cohort when it was compared with the vehicle cohort (Fig. 1A and B).
Consistent with clinical observations, gemcitabine treatment alone had no statistically significant effect on tumor growth. Tumors in mice treated with single–agent nab-paclitaxel (mean, 170% ± 15%) did not significantly differ from the gemcitabine cohort (P = 0.12). Treatment with nab-paclitaxel/gemcitabine resulted in significantly smaller tumors (mean, 140% ± 15%) as compared with gemcitabine (mean, 234% ± 32%; P < 0.01) and vehicle (mean, 278% ± 33%; Supplementary Fig. S1D). Importantly, 2 tumors in the nab-paclitaxel/gemcitabine cohort regressed after only 8 days of treatment (Fig. 1C). Because nab-paclitaxel is formulated with human serum albumin, we were unable to treat mice continuously to assess longer-term survival benefit because of the development of a mouse anti-human albumin humoral immune response (Supplementary Fig. S1E).
nab-Paclitaxel Treatment Targets Tumor Epithelial Cells
Gemcitabine and paclitaxel are chemotherapeutic agents that have been shown to elicit their antitumoral effects through induction of apoptosis or a cell-cycle arrest in G1 or G2–M, respectively. Although KPC cells display similar sensitivity to paclitaxel and nab-paclitaxel in vitro, the elevated maximum tolerated dose in vivo permitted increased intratumoral paclitaxel levels in the nab-paclitaxel–treated cohort (Fig. 2A and Supplementary Fig. S2A). In vitro, cells derived from KPC tumors are much more sensitive to gemcitabine than taxanes, and pretreatment with paclitaxel sensitizes cells to gemcitabine (Fig. 2A and B). Similarly, treatment with both drugs yielded a significant increase in apoptosis in tumors treated with nab-paclitaxel/gemcitabine compared with gemcitabine alone, whereas there were no significant changes in proliferation (Fig. 2C and D). This finding correlated with the appearance of aberrant mitotic figures that contained an abundance of phosphorylated histone H3 (Supplementary Fig. S2B and C). Necrotic areas were present in the majority of tumors but did not significantly differ among the treatment groups (Supplementary Fig. S2D).
Contrary to the observation that nab-paclitaxel promotes stromal disruption in a human xenograft model (5), histologic assessment did not reveal any evidence for changes in stromal content or composition (Supplementary Fig. S2E). The vast majority of apoptotic cells were E-cadherin-expressing neoplastic cells rather than α-smooth muscle actin (α-SMA)–expressing stromal cells, and these apoptotic cells were significantly increased only in nab-paclitaxel/gemcitabine–treated mice (Fig. 2E and Supplementary Fig. S2F). Moreover, neither intratumoral α-SMA content nor collagen density significantly changed upon treatment with nab-paclitaxel (Supplementary Fig. S3A–D). In support of the lack of effect upon stromal cells in KPC tumors, SPARC levels remained unchanged upon treatment (Supplementary Fig. S3E–F). Therefore, we concluded that the antitumor effect of nab-paclitaxel, in particular in combination with gemcitabine, is mediated by induction of apoptosis in tumor cells rather than stromal cells.
nab-Paclitaxel Promotes Elevated Intratumoral Gemcitabine Levels
We have previously demonstrated that treatment with the hedgehog inhibitor IPI-926 promotes gemcitabine delivery, resulting in enhanced antitumor effects and a doubling of survival time (3). We therefore wanted to determine whether the enhanced antitumor activity of nab-paclitaxel/gemcitabine stemmed from increased drug delivery. By using a highly sensitive method, we examined the intratumoral levels of the gemcitabine prodrug 2′,2′-difluorodeoxcytidine (dFdC), as well as its inactivated and activated metabolites 2′,2′-difluorodeoxyuridine (dFdU) and gemcitabine triphosphate (dFdCTP), respectively (20). Notably, we found that combination treatment with nab-paclitaxel elevated the dFdC:dFdU ratio and increased the amount of dFdCTP in tumors (Fig. 3A and B, Supplementary Table S1).
Conversely, paclitaxel concentrations were not significantly different between the nab-paclitaxel/gemcitabine group and the single-agent nab-paclitaxel cohort, suggesting that overall drug delivery was not affected (Fig. 3C). Unlike treatment with IPI-926, treatment with nab-paclitaxel did not affect vascular density or structure, as measured by microvascular density or mean vascular lumen area, respectively (Supplementary Fig. S4A and B). Finally, we found that the treatment of cultured PDA cells with free paclitaxel significantly elevated dFdCTP levels, indicating that the chemotherapeutic component in nab-paclitaxel directly affects the metabolism of gemcitabine independent of any alterations in vascular delivery (Fig. 3D).
nab-Paclitaxel Decreases Cytidine Deaminase Protein Levels
To assess the mechanism of increased levels of dFdCTP in tumors, we performed real-time PCR on RNA extracted from bulk tumor for a variety of enzymes involved in gemcitabine transport and metabolism. Among these, only 2 genes were significantly downregulated (Ent2 and Tk2) and one gene was upregulated (Cnt3; Supplementary Fig. S5A); however, decreased expression of Ent2 and Tk2 would be predicted to decrease rather than enhance the formation of dFdCTP. The lack of commercially available antibodies against murine Cnt3 has prevented us from further investigating this gene; however, siRNA-mediated knockdown of Cnt3 had no effect on the sensitivity of tumor cells to gemcitabine (Supplementary Fig. S5B).
Conversely, knocking down Ent1, an established gemcitabine transporter, decreased sensitivity to gemcitabine, whereas depletion of Cda, the primary gemcitabine catabolic enzyme, increased sensitivity to gemcitabine (Supplementary Fig. S5B). A subset of proteins for which reliable antibodies were available was examined in bulk tumor cell lysates. Strikingly, protein levels of Cda were lower in both the nab-paclitaxel and gemcitabine/nab-paclitaxel cohorts, whereas expression of deoxycytidine kinase and equilibrative nucleoside transporter 2 remained unchanged (Fig. 4A). Immunohistochemical analysis revealed that Cda is primarily expressed in the tumor epithelial cells and that treatment with nab-paclitaxel decreased its expression (Fig. 4B).
To determine whether this phenotype was attributable to a direct effect on tumor cells or indirectly mediated through the microenvironment, we assessed the effects of paclitaxel on cultured KPC tumor cells in vitro. Whereas the mRNA levels of Cda were not altered by treatment with free paclitaxel in culture, protein levels were substantially reduced, indicating that paclitaxel can act directly on tumor cells (Fig. 4C and D). Treatment of cells with the proteasome inhibitor MG132 reversed the effects of paclitaxel on Cda, indicating that paclitaxel regulates Cda protein stability through a posttranslational mechanism (Fig. 4E).
Paclitaxel treatment generates reactive oxygen species (ROS) that result in a more oxidized intracellular environment that can be reverted with the free radical scavenger N-acetylcysteine (NAC; Fig. 5A and B). Considering the relative abundance of cysteine residues in Cda and the finding that 2 of these cysteines are highly reactive (21), we determined whether paclitaxel-induced ROS had an effect on Cda. The paclitaxel-mediated decrease in Cda protein correlated with the induction of the antioxidant gene heme oxygenase (Fig. 5C). Conversely, treatment with NAC prevented the reduction in Cda protein levels. Importantly, NAC also inhibited the paclitaxel-mediated increase in dFdCTP, indicating that ROS is required for the effect of paclitaxel on gemcitabine activation (Fig. 5D). This observation was not restricted to paclitaxel because cisplatin, but not gefitinib, also reduced Cda levels, induced ROS, and elevated dFdCTP levels in cultured pancreatic cancer cells (Supplementary Fig. S6).
Although gemcitabine exhibits potent cytotoxicity against PDA cells in vitro, its short half-life may contribute to its relatively weak antitumor activity in vivo. Indeed, methods that increase gemcitabine delivery (3) or stability (22) have been proposed to circumvent this problem clinically. Taxanes are also active in pancreatic cancer xenografts and patients, although treatment is limited by systemic toxicity (23, 24). nab-Paclitaxel is a solvent-free formulation composed of paclitaxel and human albumin with a mean particle size of 130 nm. It offers several advantages over solvent-based paclitaxel, including increased water solubility that obviates Cremophor EL-based toxicities. In addition, albumin is hypothesized to target paclitaxel to stromal-rich tumors and thereby increase the local concentration. Although combinations of gemcitabine and taxanes have demonstrated antitumor activity in patients with PDA, its toxicity has limited its use in the clinic (25). Accumulating clinical data support the combination of nab-paclitaxel and gemcitabine as an active regimen for patients with PDA; therefore, understanding the mechanisms of sensitivity will be necessary to prevent eventual therapeutic relapse.
A recently published phase I/II clinical trial for stage IV patients demonstrated that the addition of nab-paclitaxel to gemcitabine has tolerable adverse effects and robust antitumor activity (5). Although the study was not designed to assess clinical efficacy, the median survival achieved with nab-paclitaxel/gemcitabine (12.2 months) is comparable with results for FOLFIRINOX [5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (11.1 months)]and substantially better than gemcitabine monotherapy (6.8 months) in a phase III trial with comparable patients (26). Our results indicate that nab-paclitaxel/gemcitabine treatment effectively prevents tumor growth and uniquely causes tumor regression in some mice. Conversely, tumors treated with gemcitabine more than doubled in size during this time period. Although nab-paclitaxel monotherapy elicits some antitumor activity, it fails to cause any tumor regression in the KPC model. Together, these data suggest that nab-paclitaxel/gemcitabine combination therapy offers great potential for future use in the treatment of advanced pancreatic cancer.
Concurrent with our data, work with a xenograft model of PDA has shown that combination treatment with nab-paclitaxel and gemcitabine exhibits synergistic antitumor activity and improved drug delivery (5). Increased drug delivery was hypothesized to stem from stromal depletion and subsequent reactive angiogenesis through a mechanism similar to what has been described for IPI-926 (3). Conversely, we failed to demonstrate any measurable effect on the tumor stroma of KPC mice. One possible explanation for these disparate results may be the different dosing regimens. Although we gave the maximum tolerated dose, Von Hoff and colleagues (5) administered nab-paclitaxel as a low-dose metronomic therapy. Furthermore, stromal depletion occurred after 28 days of treatment, a time frame we could not assess because of the development of an acquired immune response to the human albumin component of nab-paclitaxel after 8 days of treatment. Another key difference is our use of a genetically engineered model that develops autochthonous tumors instead of a subcutaneous transplantation model in which human tumor cells must interact with murine stromal cells in an immune-compromised mouse. This aberrant microenvironment may create conditions that render the stroma more sensitive to chemotherapeutic treatment.
Although our study did not reveal stromal depletion, both studies concluded that treatment with nab-paclitaxel elevates intratumoral gemcitabine levels. Interestingly, paclitaxel has previously been shown to alter gemcitabine pharmacokinetics in both plasma samples and non–small cell lung cancer cell lines (27–29); however, the mechanism of action was not determined. Here, we reveal that nab-paclitaxel treatment decreased protein levels of cytidine deaminase. Native gemcitabine, dFdC, is deaminated into the metabolite dFdU, which accounts for approximately 80% of the administered dose, with only 5% of native gemcitabine excreted unchanged in the urine within the first 6 hours (30, 31). Cda is ubiquitously expressed in mice and humans and can inactivate dFdC into dFdU in both plasma and cells (32, 33). Notably, recent in vitro and in vivo data have provided the first evidence that high Cda expression is associated with gemcitabine resistance, and a small study in pancreatic cancer patients showed that Cda ultrametabolizers were 5 times more likely to progress after gemcitabine-based therapy (30, 34, 35). Conversely, functionally deficient Cda has been associated with an increased risk of experiencing severe or even lethal adverse effects in patients (36, 37).
In our model, we found Cda protein levels, but not RNA levels, to be decreased upon treatment with nab-paclitaxel paralleled by a significant increase in dFdCTP and improved therapeutic efficacy. In vivo, Cda was primarily expressed by tumor cells, and the addition of paclitaxel to various KPC tumor cell lines consistently reduced Cda protein levels. Interestingly, the molecular mechanism for Cda degradation is mediated by paclitaxel-induced ROS. Upon ROS induction, Cda destabilizes and ultimately results in increased levels of active cytotoxic dFdCTP, an effect that is reversed by the ROS scavenger NAC. Although we found that other chemotherapeutic agents, such as cisplatin, are also capable of inducing ROS in vitro, the dramatically reduced toxicity profile of the nab-paclitaxel formulation allowed us to administer larger doses in vivo to execute the synergistic effects on gemcitabine metabolism within the range of relatively mild side effects.
In conclusion, we have used a GEMM of pancreatic cancer to identify a mechanism for the synergistic antitumor effects of the combination of nab-paclitaxel and gemcitabine. nab-paclitaxel exhibits monotherapeutic antineoplastic effects and simultaneously depresses Cda levels through induction of ROS to stabilize gemcitabine and thereby sensitize the PDA tumor to combination treatment. These data uncover novel insight into the antitumor activity of nab-paclitaxel and provide a distinct mechanism for improving gemcitabine delivery to pancreatic tumors that warrants further investigation in the clinical setting.
Cell lines were derived from our murine KPC tumors as previously described (16) and maintained in DMEM (41966029; Invitrogen) + 10% FBS (SH30070.03; HyClone). Protein lysates were obtained by the use of RIPA buffer with protease and phosphatase inhibitors (38). Tetrahydrouridine (Merck) was dissolved in PBS and used as a positive control for Cda inhibition. Paclitaxel (T7191; Sigma-Aldrich), docetaxel (01885; Sigma-Aldrich), MG132 (474790; Merck), and gefitinib (G-4408; LC Labs) were dissolved in dimethyl sulfoxide, whereas cisplatin (P4394; Sigma-Aldrich), NAC (A9165; Sigma-Aldrich), and gemcitabine (Addenbrookes) were dissolved in saline and used as indicated. Cell viability experiments were performed via Cell Titer-Glo (G7570; Promega) or MultiTox-Glo Multiplex Cytotoxicity Assays (G9270; Promega) according to the manufacturer's recommended protocols. Intracellular GSH levels were measured via GSH Glo (V6911; Promega) according to the manufacturer's recommended protocols.
The KPC mice have been described previously (16). KPC mice develop advanced and metastatic pancreatic ductal adenocarcinoma with 100% penetrance at an early age, recapitulating the full spectrum of histopathologic and clinical features of human PDA. Mice were housed at a 12-hour light/12-hour dark cycle. All procedures were conducted in accordance to the institutional and national guidelines.
Pancreatic tissue samples were immediately placed in an RNA later solution (QIAGEN) and stored for at least 24 hours at 4°C and then snap-frozen until they were processed. Total RNA was isolated by use of the QIAGEN TissueLyser and QIAGEN RNeasy kit. cDNA was synthesized from 1 μg of RNA using the Applied Biosystems QPCR cDNA Synthesis Kit (Applied Biosystems) and analyzed by quantitative real-time PCR on a 7900HT Real-Time PCR system using relative quantification (ΔΔCt) with the Taqman gene expression assays (Applied Biosystems). FAM-labeled assays are listed in the Supplementary Methods.
Western Blot Analysis
Western blots were performed as previously described (38). The following primary antibodies were used: heat shock protein 90, or Hsp90 (4874; Cell Signaling), phospho-ERK1/2 (4370; Cell Signaling), phospho-EGFR (4407; Cell Signaling), actin (I-19; Santa Cruz Biotechnology, Inc.), Cda (ab82346; Abcam), equilibrative nucleoside transporter 2 (ab48595; Abcam), and deoxycytidine kinase (ab96599; Abcam). Membranes were incubated with secondary horseradish peroxidase antibodies (Jackson ImmunoResearch) and developed by use of the ECL detection system (GE Healthcare).
Liquid Chromatography–Tandem Mass Spectrometry of Gemcitabine and Paclitaxel
dFdC, dFdU, and dFdCTP
Fresh-frozen tumor samples and cell pellets were processed and analyzed on liquid chromatography–tandem mass spectrometry (LC-MS/MS) as previously described (20). To summarize in brief, LC-MS/MS was performed on a TSQ Vantage triple stage quadrupole mass spectrometer (Thermo Scientific) fitted with a heated electrospray ionization (HESI-II) probe operated in positive and negative mode at a spray voltage of 2.5 KV, capillary temperature of 150°C. Quantitative data acquisition was performed with LC Quan2.5.6 (Thermo Fisher Scientific).
Fresh-frozen tumor samples were processed and analyzed for paclitaxel concentrations with the use of LC-MS/MS. To summarize in brief, samples were extracted with 90:10 acetonitrile/methanol, and LC-MS/MS was performed on a SCIEX API 4000TM mass spectrometer (Applied Biosystems/MDS SCIEX). Deuterated paclitaxel (d5-paclitaxel; Moravek) was used as the internal standard. Instrument control and quantitative data acquisition were performed by Analyst Version 1.42 (Applied Biosystems-MDS Sciex).
Tissues were fixed in 10% neutral buffered formalin for 24 hours and transferred to 70% ethanol. Tissues were embedded in paraffin, and 3- to 5-μm sections were processed for hematoxylin and eosin staining, immunohistochemistry, and immunofluorescence by the use of standard protocols as previously described (3). The following antibodies were used: SPARC (15274-1-AP; Proteintech), α-SMA (1A4; Dako), Cda (ab82346; Abcam), E-cadherin (612130; BD Pharmingen), Cleaved Caspase-3 (9661; Cell Signaling Technology), and CD31 (553370; BD Pharmingen). Images were acquired on an Olympus BX51 microscope or an Aperio XT automated scanning system and Imagescope 10 software (Aperio). More information can be found in Supplementary Methods.
ROS were quantified essentially as described (39). To summarize in brief, cells were treated as indicated and subsequently incubated with CM-H2DCFDA (C6827; Invitrogen) for 30 minutes in PBS, trypsinized, and analyzed via flow cytometry.
Statistical analysis was performed with the use of GraphPad Prism version 5.01 (GraphPad Software). The Mann–Whitney nonparametric t test was used, and results are presented as mean ± SE. P< 0.05 was considered to be significant.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
K.K. Frese, A. Neesse, and D.A. Tuveson conceived of and designed the experiments. A. Neesse, K.K. Frese, and M.P. Lolkema performed animal experiments. K.K. Frese performed cell culture experiments. K.K. Frese, N. Cook, T.E. Bapiro, and D.I. Jodrell designed and carried out gemcitabine pharmacokinetic experiments. K.K. Frese, A. Neesse, and D.A. Tuveson wrote the manuscript. All authors reviewed the manuscript.
This research was supported by the University of Cambridge and Cancer Research UK, The Li Ka Shing Foundation, Hutchison Whampoa Limited, and the NIHR Cambridge Biomedical Research Centre. K.K. Frese was supported under the NIH Ruth L. Kirschstein National Research Service Award F32CA123887-01, and K.K. Frese and D.A. Tuveson were supported by the European Community Grant EPC-TM-Net 256974. A. Neesse was supported by the Deutsche Krebshilfe Mildred Scheel Postdoctoral Fellowship. N. Cook was supported by a Cancer Research UK Clinician Fellowship. M.P. Lolkema has received a Dutch Cancer Foundation Fellowship grant (UU2008-4380) to support this work. D.A. Tuveson and D.I. Jodrell are Group Leaders in the Cancer Research UK Cambridge Research Institute. T.E. Bapiro is supported by Cancer Research UK.
We thank Dan Von Hoff for sharing his data before publication. We thank Frances Connor, Paul Mackin, and Lisa Young for maintenance and management of mouse colonies, as well as staff from the Cambridge Research Institute BRU, histology core, and pharmacokinetics core. Paclitaxel concentrations were measured by Sherri Ci of Abraxis Bioscience.
Note: Supplementary data for this article are available at Cancer Discovery Online (http://www.cancerdiscovery.aacrjournals.org).
- Received September 23, 2011.
- Revision received January 16, 2012.
- Accepted January 17, 2012.
- ©2012 American Association for Cancer Research.